Celldex Therapeutics (CLDX) Shares Outstanding (2010 - 2026)

Celldex Therapeutics' Shares Outstanding history runs 17 years deep, the most recent figure standing at $66.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding changed 0.28% year-over-year to $66.6 million; the TTM figure through Mar 2026 stood at $66.6 million (changed 0.28% YoY), while the FY2025 annual figure was $66.5 million, changed 0.26% from the prior year.
• Shares Outstanding was $66.6 million for Q1 2026 at Celldex Therapeutics, roughly flat from $66.5 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $66.6 million in Q1 2026 to a low of $46.8 million in Q1 2022.
• Historically, Shares Outstanding has averaged $57.8 million across 5 years, with a median of $65.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding jumped 40.37% in 2024, then grew 0.15% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $47.2 million in 2022, then advanced by 18.4% to $55.9 million in 2023, then grew by 18.77% to $66.4 million in 2024, then increased by 0.26% to $66.5 million in 2025, then grew by 0.03% to $66.6 million in 2026.
• The last three Shares Outstanding figures came in at $66.6 million (Q1 2026), $66.5 million (Q4 2025), and $66.4 million (Q3 2025), per Business Quant data.